Item 5.07. Submission of Matters to a Vote of Security Holders.

REGENXBIO Inc. (the "Company") held its 2020 annual meeting of stockholders on May 29, 2020 (the "Annual Meeting"). The final voting results are set forth below. For more information on the proposals, see the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 8, 2020 (the "Proxy Statement").



Proposal 1: By the following vote, the following three persons were elected to
serve as Class II directors until the Company's 2023 annual meeting of
stockholders:

Nominee                         Votes For    Votes Withheld   Broker Non-Votes
Donald J. Hayden, Jr.           25,528,986     3,946,044         2,952,587
A.N. "Jerry" Karabelas, Ph.D.   25,061,892     4,413,138         2,952,587
Daniel Tassé                    15,819,958     13,655,072        2,952,587

Proposal 2: By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020:

Votes For Votes Against Votes Abstaining Broker Non-Votes 32,380,618 21,402

            25,597               0

Proposal 3: By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement:



Votes For    Votes Against   Votes Abstaining   Broker Non-Votes
28,212,090     1,239,071          23,869           2,952,587

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits

 Exhibit
   No.           Description

   104           The cover page from this Current Report on Form 8-K, formatted in
                 Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses